<DOC>
	<DOCNO>NCT03076814</DOCNO>
	<brief_summary>Investigator test hypothesis short term PDE5A inhibition ( tadalafil ) reduce post-exercise edema MRI males Becker Muscular Dystrophy .</brief_summary>
	<brief_title>Functional Muscle Ischemia With Tadalafil Treatment Becker Muscular Dystrophy</brief_title>
	<detailed_description>Becker muscular dystrophy ( BMD ) rare , progressive fatal muscle disease . Tadalafil approve FDA treatment erectile dysfunction pulmonary hypertension . This class medication improve muscle blood flow mouse model muscular dystrophy , prevent post-exercise muscle edema , alleviate post-exercise muscle fatigue . To begin translate work mouse actual patient muscular dystrophy , Investigator group recently demonstrate single dose tadalafil improve blood flow regulation boys Duchenne muscular dystrophy men BMD . Investigator wish test hypothesis acute treatment Tadalafil prevent post-exercise muscle edema men BMD . Investigator recruit men BMD , healthy age-matched control , age 15-55y ambulatory without heart failure . Visit 1 : Participants undergo informed consent , physical exam medical history screening , electrocardiogram , blood pressure monitoring , blood chemistry test , echocardiogram ( ejection fraction measurement ) , evaluation skeletal muscle blood flow . Patients , control , also undergo muscle biopsy . Visit 2 - 4 : Participants undergo baseline magnetic resonance image forearm muscle , follow rhythmic forearm muscle exercise ( handgrip ) . MRI repeat 2- , 4- , 24- , 48 hour follow rhythmic handgrip exercise . Patients BMD randomize 3:1 fashion tadalafil vs. placebo . Visit 5-7 : Using standard double-blind cross-over design , patient treat either tadalafil placebo . Magnetic resonance image forearm muscle perform establish baseline measurement . Patients repeat rhythmic handgrip exercise protocol perform Visit 2 , follow MRI 2- , 4- , 24- , 48 hour follow exercise .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Patient BMD diagnosis BMD confirm muscle biopsy DNA analysis age 1555 year age ambulatory clinical evidence heart failure hypertension , diabetes , heart failure standard clinical criterion elevate BNP ( brain natriuretic peptide ) level ( &gt; 100 pg/ml ) leave ventricular ejection fraction &lt; 50 % wheelchair bound cardiac rhythm disorder , specifically : rhythm sinus , sinoventricular tachycardia , atrial fibrillation , ventricular tachycardia continuous ventilatory support liver disease renal impairment contraindication tadalafil ( use nitrate , alphablockers , Cytochrome P450 ( CYP3A ) inhibitor , amlodipine , phosphodiesterase 5A inhibitor ) Healthy Control Participants age 1555 year age ambulatory clinical evidence heart failure hypertension , diabetes , heart failure standard clinical criterion elevate BNP ( brain natriuretic peptide ) level ( &gt; 100 pg/ml ) leave ventricular ejection fraction &lt; 50 % cardiac rhythm disorder , specifically : rhythm sinus , sinoventricular tachycardia , atrial fibrillation , ventricular tachycardia liver disease renal impairment unsatisfactory completion sympatholysis protocol BMI &lt; 35</criteria>
	<gender>Male</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>